Basic Science for Clinicians

Cellular Mechanisms of Aortic Valve Calcification

Jane A. Leopold, MD

The earliest description of calcific aortic stenosis is attributed to the French physician Lazare Rivière who, in 1663, reported the necropsy findings from a patient with palpitations, progressive dyspnea, and loss of peripheral pulses. He noted left ventricular enlargement and identified large calcane-like masses obstructing the left ventricular outflow to the aorta.1 Although other reports followed, the debate about the etiology of aortic valve calcification (AVC) did not begin until much later.1 Although calcification was originally attributed to endocarditis, in 1846, Hasse challenged this theory by suggesting that a degenerative process occurred within the valve itself to initiate ossification.1 In 1904, Möenckeburg authored the first detailed description of AVC in which he reported that this pathology likely occurred as a result of calcium deposition on valve cusps that had become sclerotic. He described 2 mechanisms to explain this phenomenon: degeneration within the layers of the valve leaflets near the sinuses of Valsalva that propagated toward the tips of the cusps or sclerotic changes of the aorta that extended to involve the valve cusps.1 Within the past 20 years, there has been a tremendous resurgence in interest in advancing these early hypotheses to identify the cellular and molecular mechanisms that initiate AVC owing to the high prevalence of this disease, its associated morbidity and mortality, and the emerging idea that therapies that target these processes could increase the durability of surgically implanted and transcatheter bioprosthetic valves.

Epidemiology of Aortic Valve Disease

Recent estimates indicate that aortic valve disease is common in the US adult population and contributes to >28,000 deaths and 48,000 hospitalizations annually.2 Worldwide, population-based studies have revealed that aortic valve disease is the most frequently observed valve pathology and is present in up to 43% of patients presenting with valvular heart disease.3 In individuals ≥65 years of age, aortic sclerosis is present in 29% of individuals, whereas the prevalence of aortic stenosis has been estimated to be between 2% and 9%, depending on the population studied.4,5 Aortic sclerosis is not a benign finding because it is associated with an approximately 50% increased risk of myocardial infarction and cardiovascular death and the rate of progression to aortic stenosis is approximately 1.7% per year.6,8 AVC is not limited to native aortic valves and has been shown to be the principal cause of bioprosthetic aortic valve failure with calcification occurring in areas of high biomechanical stress.7,8 Longitudinal studies have shown that at 15 years after implantation, there is a 30% to 60% incidence of structural valve degeneration, in part, as a result of calcification.9 With the advent of transcatheter aortic valve replacement, it remains unknown if these valves will also be subject to the same rate of calcific valve degeneration and failure owing to the absence of long-term follow-up.

Aortic Valve Structure and Resident Cell Types

In humans, the aortic valve is an avascular trileaflet structure that is attached to the aorta through a fibrous annulus (Figure 1).10 Typically, the leaflets are ≤1 mm thick and are comprised of an outer layer of valve endothelial cells (VECs) and 3 internal layers made up of valve interstitial cells (VICs), <5% smooth muscle cells, and myofibroblasts. These layers are known as the fibrosa, spongiosa, and ventricularis to reflect their anatomic location, cellular and extracellular matrix composition, and biomechanical properties.11,12 The VECs maintain valve homeostasis by regulating permeability, inflammatory cell adhesion, and paracrine signaling. The VICs are arranged in subpopulations within the fibrosa, spongiosa, and ventricularis layers and secrete extracellular matrix, including collagen, elastin, and glycosaminoglycans, that provide strength and elasticity to the valve. The fibrosa layer is located on the aortic side of the valve, is formed by circumferentially arranged Type I and Type III fibrillar collagen, and serves a load-bearing function. The middle spongiosa layer contains glycosaminoglycans and lubricates the fibrosa and ventricularis layers as they shear and deform during the cardiac cycle. The ventricularis layer, which is closest to the ventricular inflow side, contains collagen and radially oriented elastin fibers that are arranged to reduce radial strain.10,12 The normal valve cellular and matrix architecture may be disrupted by exposure to biochemical (ie, hypercholesterolemia, hyperglycemia) or mechanical (ie, hypertension) stress (Figure 2).13 This results in a progressive thickening and fibrosis of the leaflets with evidence of inflammation, neovascularization, the appearance of ectopic mesenchymal tissue, and calcification. Before the appearance of calcification, early changes in the valve tissue include the infiltration of inflammatory cells, disruption of the elastic laminae, disorganized...
matrix deposition, and lipid accumulation at the valve surface with the appearance of microcalcifications.\textsuperscript{11,12,14} The calcification process may include formation of actual lamellar bone that contains osteoblasts and bone marrow. In addition, chondrocytes, cartilage, and endochondral calcification may also be present.\textsuperscript{15,16} The calcific nodules and lesions tend to occur primarily in the fibrosa layer and extend to the aortic side of the valve where they ultimately compromise valve integrity and function.\textsuperscript{15}

Cellular and Molecular Mechanisms That Modulate AVC

It is now recognized that AVC does not result from simple passive deposition of calcium–phosphate complexes on the injured valve surface but, instead, is an active process that involves valve, circulating, and bone marrow-derived cells. Studies have implicated in situ transition of VICs to osteoblast-like bone-forming cells,\textsuperscript{17–27} endothelial-to-mesenchymal transition of VECs,\textsuperscript{18–20,28} matrix vesicle formation giving rise to microcalcific nodules,\textsuperscript{29–32} and lipid accumulation as key mediators of AVC.\textsuperscript{33–42} These processes have been attributed to activation of VICs, dysfunction or denudation of VECs, infiltration of inflammatory and immune cells,\textsuperscript{17,43–51} and downregulation of local or circulating inhibitors of calcification.\textsuperscript{52–59} These events, in turn, promote neoangiogenesis,\textsuperscript{60–64} extracellular matrix remodeling and fibrosis,\textsuperscript{12,22,65–68} and calcification of the valve leaflets.

**Figure 1.** Cellular architecture of the aortic valve. Valve endothelial cells (VECs) line the outer surface of the valve and function as a barrier to limit inflammatory cell infiltration and lipid accumulation. The 3 middle layers of the valve are the fibrosa, spongiosa, and ventricularis. These layers contain valve interstitial cells (VICs) as the predominant cell type. The fibrosa is nearest the aortic side of the valve, contains Type I and Type III fibrillar collagen, and serves a load-bearing function. The spongiosa contains glycosaminoglycans (GAGs) that lubricate the fibrosa and ventricularis layers as they shear and deform during the cardiac cycle. The ventricularis contains elastin fibers to decrease radial strain. Adapted from Rajamannan et al.\textsuperscript{10}

**Figure 2.** Spectrum of aortic valve calcification. \textbf{A}, Gross anatomic specimen of a minimally diseased aortic valve demonstrating few nodules (left) and a severely diseased calcified valve with evidence of nodular calcifications (arrow) on the valve cusps (right). \textbf{B}, Histological findings in the early stages of valve calcification include abundant subendothelial lipid and extracellular matrix with displacement of the elastic lamina (arrow; left). As the disease progresses, lipid, cells, and extracellular matrix are increased with evidence of breakdown and displacement of the elastic lamina (arrow). Verhoeff-van Gieson stain, 100×. Reprinted with permission from Freeman and Otto.\textsuperscript{13}
These procalcific processes are counterbalanced by local and circulating inhibitors of calcification suggesting that decreased expression or activity of these mediators may also contribute to pathological cardiovascular calcification. Matrix Gla protein (MGP), a γ-carboxyglutamic acid-rich and vitamin K-dependent protein, prevents calcification by inhibiting bone morphogenetic protein (BMP) signaling. MGP levels have been shown to be significantly lower in patients with AVC as compared with individuals without valve disease. Experimental models of MGP deficiency develop early valve calcification, whereas transgenic mouse models that overexpress MGP are protected, even in the setting of hypercholesterolemia. These findings suggest that a decrease in MGP expression or activity may contribute to the progression of AVC. MGP activity is dependent on its carboxylation status and vitamin K availability: warfarin, an inhibitor of γ-carboxylase and vitamin K epoxide reductase, inhibits MGP activity and use of this drug has been shown to be associated with AVC. One study of 1155 patients found a significant association between the use of warfarin and the risk of calcification (unadjusted OR, 1.71; 95% CI, 1.34–2.18).

Fetuin-A is a liver-derived protein that is a potent circulating inhibitor of calcification. Fetuin-A acts by binding clusters of calcium and phosphate to stabilize these ions and prevent uptake by cells. Fetuin-A deficiency is known to be associated with soft tissue calcification in experimental models and humans and serum fetuin-A levels are lower in patients with AVC compared with control subjects. Similarly, when stratified by fetuin A levels, individuals within the highest fetuin-A tertile had a significantly lower risk of developing of AVC and lower AVC scores on multislice spiral CT compared with those in the lowest tertile. Together these findings suggest that valve remodeling and calcification occur through the activation of procalcific cellular and molecular processes and that the activity of circulating inhibitors of calcification is insufficient to prevent AVC.

**Cellular Mechanisms of AVC**

**In Situ Transition of VICs to Osteoblast-Like Bone-Forming Cells**

One mechanism implicated in the pathogenesis of AVC posits that normally quiescent VICs become activated and undergo a phenotype transition to become osteoblast-like bone-forming cells. These activated VICs are responsive to typical osteogenic mediators such as BMPs. BMPs are members of the transforming growth factor-β superfamily, stimulate osteoblasts to initiate skeletal bone formation, and have been implicated in vascular calcification (reviewed in Bostrom et al14).

It is likely that BMPs play an important role in the pathogenesis of AVC (Figure 3). In experimental models, activated endothelial cells have been shown to secrete BMP-2 and BMP-4 in response to changes in laminar flow patterns and BMP-2 has been detected in VICs isolated from the aortic valve of aged rats. BMPs stimulate calcification by activating Smad and Wnt/β-catenin signaling as well as upregulating expression of the osteochondrogenic transcription factor Msx2. These signaling pathways converge to induce expression of the master osteoblast transcription factor Runx2. Once Runx2 is expressed, cells are committed to an osteoblast lineage, upregulate expression of calcification-related proteins, including osteopontin, bone sialoprotein II, and osteocalcin, and undergo calcification.

There is evidence to indicate that BMP signaling is activated in calcified valves. Smad 1/5/8 and Runx2 have been detected in calcified human aortic valves and levels of these markers have been shown to increase before there is evidence of valve leaflet calcification. These findings correlate well with the observation that there is a significant increase in the Runx2-dependent calcification-related...
proteins osteopontin (7.4-fold) and bone sialoprotein II (5.8-fold) in calcified human valves.\textsuperscript{24} 

BMPs also activate the Wnt/\(\beta\)-catenin signaling pathway to increase the expression of alkaline phosphatase, which is also necessary to facilitate calcification.\textsuperscript{14} Wnt proteins belong to a family of secreted lipid-modified polypeptide ligands that bind to receptor complexes of frizzled protein/lipoprotein receptor-related protein 5 or 6 leading to an accumulation of \(\beta\)-catenin in the nucleus. Activation of this signaling pathway in experimental models of AVC and explanted human valves has been confirmed by demonstrating the expression of the Wnt ligand Wnt3a, the coreceptor lipoprotein receptor-related protein 5, and nuclear \(\beta\)-catenin in calcified valve tissue.\textsuperscript{16,25,26} 

BMPs also increase the expression of the osteochondrogenic transcription factor Msx2 that is important for intramembranous bone formation. Msx2 has been identified in valves from experimental models of AVC where it is localized to areas of calcification.\textsuperscript{27} Because Msx2-positive cells secrete Wnt ligands such as Wnt3a, these cells may upregulate Runx2 expression in adjacent VICs.\textsuperscript{28} Downstream of the BMP-Smad and BMP-Wnt/\(\beta\)-catenin signaling pathways are the transcription factors osterix and NFATc1. These transcription factors have also been shown to be necessary for bone formation and have been detected in activated VICs and inflammatory cells in calcified human aortic valves.\textsuperscript{14,23} Taken together, these studies indicate that BMPs are capable of driving VICs to an osteoblast-like phenotype in which these cells express all of the markers of functional osteoblasts, elaborate bone matrix proteins, and mineralize to form calcific nodules typical of AVC.

**Endothelial-to-Mesenchymal Transition**

The primary function of VECs is to maintain valve homeostasis; however, valve endothelium may also undergo differentiation to osteoblast-like cells as a result of endothelial-to-mesenchymal-transition (EnMT). During this process, VECs lose their endothelial cell properties, no longer express endothelial-specific markers such as vascular endothelial cadherin, acquire phenotypic characteristics of mesenchymal cells or myofibroblasts, and express \(\alpha\)-smooth muscle actin, Type I collagen, and vimentin.\textsuperscript{20,28} These “transformed” VECs also exhibit increased motility and may migrate into surrounding tissues.\textsuperscript{20} This phenomenon may be stimulated by transforming growth factor-\(\beta\), the transcription factor Msx2, and \(\beta\)-catenin signaling, all of which are present in calcifying aortic valves. Once EnMT occurs, VECs may participate in pathological fibrosis of the valve and/or undergo osteogenic differentiation through the same mechanisms as VICs exposed to BMPs, calcify, and contribute to AVC.\textsuperscript{14}

Although EnMT is known to play a prominent role in the endocardial cushion during valve formation, much of the data to implicate EnMT in valve calcification have been derived from preclinical studies of the mitral valve.\textsuperscript{19} Experimental models using ovine mitral VEC clones have found that select clones underwent EnMT when stimulated with transforming growth factor-\(\beta\) and that these cells were capable of osteogenic and chondrogenic differentiation. Similarly, evidence of EnMT and bone-related proteins was observed in mitral leaflets after high levels of mechanical stretch.\textsuperscript{29} Further studies are required to determine if this mechanism of calcification is operative in human AVC.

**Inflammation and Immune Response**

Similar to atherosclerosis, AVC may also be considered an immune-inflammatory disease process. This is supported by the observation that explanted normal human aortic valves contain relatively few macrophages whereas there is abundant leukocyte and macrophage infiltration seen in explanted calcified human aortic valves.\textsuperscript{27} Valve macrophage and inflammatory cell infiltration is typically seen at sites where VECs are activated and express adhesion molecules that facilitate the recruitment and transendothelial migration of monocytes and macrophages into the valve.\textsuperscript{43,44,72} Using molecular imaging, macrophage infiltration was identified as an early event in the development of AVC in atherosclerosis-prone mouse models and macrophage burden was shown to correlate with the degree of valve calcification.\textsuperscript{44,45} In explanted human congenital bicuspid aortic valves, which are predisposed to early calcification, the density of infiltrating valve macrophages was greater than that observed for tricuspid valves.\textsuperscript{46} These areas of inflammatory cell infiltration were associated with the expression of proinflammatory cytokines that have been implicated in AVC, including tumor necrosis factor-\(\alpha\), interleukin-1\(\beta\), and receptor activator of nuclear factor \(\kappa\)-B ligand.\textsuperscript{44,47,48,72} Once present, macrophages also release matrix metalloproteases and cysteine endoproteases that lead to degradation of collagen and elastin in the valve matrix to disrupt the normal valve architecture.\textsuperscript{18,49}

There is increasing evidence to suggest a role for immune modulatory cells in AVC as well. Calcified aortic valves have been shown to contain expanded populations of T cell clones that differed from peripheral CD8 or CD4 T cell subsets. A number of the T cell clones were of CD8 lineage (cytotoxic T cells or natural killer cells), suggesting that these T cells likely participated in the pathogenesis of AVC and were not merely a secondary response.\textsuperscript{50} Other studies using flow cytometry similarly identified increased levels of activated CD8 cells and memory effector cells in the peripheral blood of patients with calcified valves, indicating a systemic adaptive immune response may be associated with AVC.\textsuperscript{51} Whether this adaptive immune response modulates other cellular processes involved in AVC has not yet been determined.

**Stem and Progenitor Cells**

In addition to VECs and VICs, bone marrow-derived cells have been shown to populate normal aortic valves and it has been suggested that these progenitor cells may participate in AVC.\textsuperscript{73} For example, mesenchymal progenitor cells, which have been identified in porcine aortic valves, have the capacity to undergo differentiation to osteoblast-like cells.\textsuperscript{74} Using clonal analyses, a high frequency of these progenitor cells were shown to possess the capacity for self-renewal, undergo osteogenic differentiation, and elaborate bone matrix in the valve.\textsuperscript{74} Other studies have determined that the local environment drives osteogenic differentiation of mesenchymal progenitor cells. When these cells were cocultured with explanted calcified valves, they differentiated toward
an osteoblastic lineage. Thus, under conditions that favor calcification, subpopulations of mesenchymal progenitors within the valve are capable of contributing to valve calcification.

Endothelial progenitor cells have also been identified in diseased aortic valves. It is now believed that at sites of endothelial injury, the function of endothelial progenitor cells is to participate in the repair process by transiently establishing residence and secreting factors that facilitate proliferation and migration of resident endothelial cells. In A VC, there is evidence to demonstrate that endothelial progenitor cells are dysfunctional and the repair process is ineffective. Individuals with calcified aortic valves were found to have a significant reduction in endothelial progenitor cell number and ex vivo functional capacity as compared with control subjects. Moreover, endothelial progenitor cells isolated from patients with A VC had increased proapoptotic caspase-3 activity and decreased telomere-repeating factor-2 expression indicating progenitor cell senescence. Thus, the combined effect of mesenchymal progenitor cell transition to osteoblast-like cells and endothelial progenitor cell dysfunction represents another cellular mechanism to promote A VC.

Other Processes Associated With A VC

Matrix Vesicle Formation and Microcalcifications
A VC has also been associated with the formation and release of matrix vesicles that serve as a nidus for calcium deposition. Matrix vesicles are important for bone and cartilage mineralization and have been implicated in ectopic vascular calcification. In the presence of high levels of calcium and/or phosphate, smooth muscle cells have been shown to release vesicles of 100 to 300 nm that are derived from the plasma membrane. These vesicles may be retained by the cells and attract calcium leading to areas of microcalcification. Although these vesicles have been shown to contain the calcification inhibitors MGP, fetuin-A, and osteoprotegerin, it is likely that encapsulation of these inhibitors in the vesicles serves as a mechanism to sequester them and render them inactive. Microcalcifications have been shown to occur under inflammatory conditions suggesting that inflammation plays a role in their genesis.

Other studies using electron microscopy have suggested that some of the 10 to 500 nm size particles present in calcified valves are actually derived from a type of bacteria referred to as nanobacteria. These particles stain positive for the profibrotic enzyme neutral endopeptidase. Similar to what has been observed during myocardial repair processes in which there is a return to the fetal gene program, expression of Twist1, which is important for endocardial cushion development and valve remodeling, has been identified in A VC in areas adjacent to calcific nodules. When overexpressed in mouse models, Twist1 leads to increased valve hypercellularity and cusp fibrosis. There is also evidence of increased thrombospondin-2, a matricellular protein that regulates extracellular matrix remodeling and fibrosis in human fibrocalcific aortic valve disease as well as the profibrotic enzyme neutral endopeptidase.

Angiogenesis and Neovascularization
Another feature of A VC is abnormal extracellular matrix remodeling. This occurs as a result of increased expression of matrix metalloproteinases-1, -2, -3, and -9 and cathepsins (S, K, V, and G) by inflammatory cells and VICs (reviewed in Chen and Simmons). Once activated, matrix metalloproteinases and cathepsins degrade collagen and elastin to form proinflammatory peptides; this process compromises valve integrity, augments the inflammatory response, and allows for the expansion of calcified nodules.

In addition to extracellular matrix degradation, there is also evidence of aberrant matrix deposition and valve fibrosis, which is extensive in A VC and contributes to the calcification of valves. Activated VICs secrete collagen, hyaluronan, and other extracellular matrix components; however, the deposition of these matrix proteins is often disorganized and alters the biomechanical properties of the valve. These changes in valve stiffness have also been shown to modulate the transition of VICs to osteoblast-like cells.

The profibrotic signaling molecule transforming growth factor-β is increased in experimental models of A VC and human valve tissue consistent with the degree of fibrosis seen in A VC. Similar to what has been observed during myocardial repair processes in which there is a return to the fetal gene program, expression of Twist1, which is important for endocardial cushion development and valve remodeling, has been identified in A VC in areas adjacent to calcific nodules. When overexpressed in mouse models, Twist1 leads to increased valve hypercellularity and cusp fibrosis. There is also evidence of increased thrombospondin-2, a matricellular protein that regulates extracellular matrix remodeling and fibrosis in human fibrocalcific aortic valve disease as well as the profibrotic enzyme neutral endopeptidase.

Histological analysis of calcified aortic valves has identified a subpopulation of cells that express the endothelial markers
levels of circulating proatherogenic oxidized low-density lipoproteins. The aortic valve content of atheroprotective high-density lipoprotein is decreased in calcified human aortic valves and is dysfunctional as demonstrated by a decrease in the activity of the high-density lipoprotein-associated antioxidant enzyme paraoxonase-1. The importance of proatherogenic lipids for valve injury and calcification was confirmed using a hypercholesterolemic mouse model with a genetic switch to induce rapid lipid lowering known as the “Reversa” mouse. Using this model, investigators demonstrated that under hypercholesterolemic conditions, there was significant lipid infiltration of the valve with valve calcification. When the genetic switch was turned on and lipid levels lowered, valve calcium deposition decreased and progression of valve calcification was halted although this did not reverse established calcification or valve dysfunction. Lipid-lowering with HMG-CoA reductase inhibitors (statins) has also been shown to decrease inflammatory cell infiltration, osteoblast bone markers, including alkaline phosphatase and Runx2, and downregulated lipoprotein receptor-related protein 5β-catenin signaling to decrease valve calcification in rabbit models of experimental hypercholesterolemia that have aortic valve disease. Despite these findings, 3 large-scale clinical trials (Simvastatin and Ezetimibe in Aortic Stenosis [SEAS], Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression [SALTIRE], and Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin [ASTRONOMER]) failed to show a benefit for statins to limit the progression of aortic valve disease and progression of valve calcification was halted although this did not reverse established calcification or valve dysfunction. Lipid-lowering with HMG-CoA reductase inhibitors (statins) has also been shown to decrease inflammatory cell infiltration, osteoblast bone markers, including alkaline phosphatase and Runx2, and downregulated lipoprotein receptor-related protein 5β-catenin signaling to decrease valve calcification in rabbit models of experimental hypercholesterolemia that have aortic valve disease. Despite these findings, 3 large-scale clinical trials (Simvastatin and Ezetimibe in Aortic Stenosis [SEAS], Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression [SALTIRE], and Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin [ASTRONOMER]) failed to show a benefit for statins to limit the progression of aortic valve disease, even after 6 months of treatment. Another possible explanation is that statins are known to promote osteoblast differentiation and calcification. Thus, in a valve in which VICs have become osteoblast-like cells, statins may actually have a procalcifying effect.

Future Directions
To date, there is no proven medical therapy to prevent or slow the progression of aortic valve disease and surgical or percutaneous valve replacement is the only curative treatment. Possible preventive strategies include medical therapy with inhibitors of the renin–angiotensin system or bisphosphonates. Observational studies have found that individuals with aortic stenosis taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers have lower rates of all-cause mortality compared to patients not receiving these medications. This finding has been attributed to improved left ventricular remodeling. Histopathologic analyses of explanted calcific native valves have revealed that treatment with these drugs was associated with less pronounced valve remodeling. Although bisphosphonates have been suggested as a therapy for aortic valve disease owing to the inverse relationship between skeletal bone and valve remodeling, a retrospective analysis of 801 female patients treated with bisphosphonates for a mean of 3.1 years revealed that the drug had no effect on freedom from aortic valve replacement or survival.

A better understanding of the cell biology of calcific aortic valve disease may, therefore, identify rational targets for the development of small molecule, gene transfer, or cell-based therapies to prevent or retard the calcification process or serve as adjuncts.
to limit bioprosthetic valve failure. Toward this end, investigators have used molecular and cell-based methodologies to modulate the cellular mechanisms of ectopic calcification with success in preclinical studies. For example, the expression of Runx2 in VICs commits these cells to an osteoblast-like phenotype. Gene transfer of small interfering RNA that targets Runx2 using adenovirus or recombinant non-viral vectors has been shown to prevent calcification both in vitro and in vivo. Other strategies have exploited the concept that ectopic calcification resembles orthotopic bone formation and focused on stimulating osteoclast differentiation and function. Osteoclasts resorb and remodel bone and osteoclasts or osteoclast-like cells have been demonstrated to be present in calcified vascular lesions where they are capable of resorbing mineral deposits. Despite this, ectopic vascular and valvular calcification does occur suggesting that either the cell number or function is insufficient to inhibit calcification. Thus, strategies to promote osteoclast recruitment or stimulate differentiation of monocytes and macrophages toward an osteoclast phenotype are areas of active investigation.

By using techniques used to deliver stem or progenitor cells to the heart, it is feasible to see how these strategies could be adapted to treat the diseased aortic valve in the cardiac catheterization laboratory using catheter-based techniques. Cells have been delivered successfully to ischemic myocardium using a NOGA-guided catheter system and direct injection. In the case of the aortic valve, NOGA guidance is not necessary and direct injection of small molecule inhibitors; osteoclasts, osteoclast-like cells, or molecules that promote transition of resident monocytes/macrophages toward an osteoclast lineage; or viral vectors encoding inhibitory RNA (Runx2, Msx2, Wnts) or RNA (MGP, fetuin-A) to the aortic side of the valve may be efficacious. Other possibilities include catheter-based delivery of a biocompatible biodegradable gel concentrated with bisphosphonates or other bone remodeling drugs to the valve leaflets; however, with this technique, it would be necessary to ensure that the gel does not interfere with leaflet performance.

**Conclusion**

Although much progress has been made in understanding the pathogenesis of AVC, the disease process is exceedingly complex and involves several different resident, circulating, and bone marrow-derived cells (Figure 5). These cells may become dysfunctional, transition to an osteoblast-like phenotype, and/or secrete procalcific factors. The net result of these cellular events is the infiltration of the valve by inflammatory or immune cells, angiogenesis and neovascularization, breakdown and aberrant matrix deposition and fibrosis, and lipid accumulation in the valve tissue. These pathological changes, in turn, are permissive for the formation of microcalcifications that ultimately form the calcific nodules typical of AVC. Therapies that target these cellular events may be readily adaptable for clinical use. Furthermore, many of these anticalcification strategies may require novel catheter-based delivery systems to deliver cells or agents to the valve and avoid systemic effects.

**Source of Funding**

This work was supported by funding from the National Institutes of Health HL105301.

**Disclosures**

None.

**References**


**Key Words:** aortic valve, calcification
Cellular Mechanisms of Aortic Valve Calcification
Jane A. Leopold

doi: 10.1161/CIRCINTERVENTIONS.112.971028

Circulation: Cardiovascular Interventions is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2012 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-7640. Online ISSN: 1941-7632

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circinterventions.ahajournals.org/content/5/4/605

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Cardiovascular Interventions can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Cardiovascular Interventions is online at:
http://circinterventions.ahajournals.org//subscriptions/